- Ladenburg Thalmann Hired as Financial
advisor -
SAN
DIEGO, Dec. 7, 2023 /PRNewswire/ -- Kintara
Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a
biopharmaceutical company focused on the development of new solid
tumor cancer therapies, today announced that its Board of Directors
has initiated a process to explore and review a range of strategic
alternatives focused on maximizing stockholder value.
Kintara has engaged Ladenburg Thalmann & Co. Inc. to act as
financial advisor for this process. There can be no assurance that
this exploration of strategic alternatives will result in the
Company entering or completing any transaction. Kintara does not
intend to make any further disclosures regarding the strategic
review process unless and until a specific course of action is
approved.
ABOUT KINTARA
Located in San Diego,
California, Kintara is dedicated to the development of novel
cancer therapies for patients with unmet medical needs. Kintara
develops therapeutics for clear unmet medical needs with reduced
risk development programs. The Company's lead program is
REM-001 Therapy for cutaneous metastatic breast cancer (CMBC).
Kintara has a proprietary, late-stage photodynamic therapy
platform that holds promise as a localized cutaneous, or visceral,
tumor treatment as well as in other potential indications.
REM-001 Therapy, which consists of the laser light source, the
light delivery device, and the REM-001 drug product, has been
previously studied in four Phase 2/3 clinical trials in patients
with CMBC who had previously received chemotherapy and/or failed
radiation therapy. In CMBC, REM-001 has a clinical efficacy to date
of 80% complete responses of CMBC evaluable lesions and an existing
robust safety database of approximately 1,100 patients across
multiple indications.
For more information, please visit www.kintara.com or
follow us on X
at @Kintara_Thera, Facebook and Linkedin.
SAFE HARBOR STATEMENT
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995, including statements regarding the Company's review of
strategic alternatives and the Company's ability to complete any
transaction as a result of the strategic review process. Any
forward-looking statements contained herein are based on current
expectations but are subject to a number of risks and
uncertainties. The factors that could cause actual future results
to differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
ability to develop, market and sell products based on its
technology; the status of the Company's clinical trials; the
topline results of the GBM AGILE Study; the Company's review of
strategic alternatives; the expected benefits and efficacy of the
Company's products and technology; the availability of substantial
additional funding for the Company to continue its operations and
to conduct research and development, clinical studies and future
product commercialization; the Company's business, research,
product development, regulatory approval, marketing and
distribution plans and strategies; and global unrest. These
and other factors are identified and described in more detail in
the Company's filings with the SEC, including the Company's Annual
Report on Form 10-K for the year ended June
30, 2023, the Company's Quarterly Reports on Form 10-Q, and
the Company's Current Reports on Form 8-K.
CONTACTS
Investors:
Robert E. Hoffman
Kintara Therapeutics
rhoffman@kintara.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/kintara-therapeutics-announces-review-of-strategic-alternatives-302008600.html
SOURCE Kintara Therapeutics